Interna Therapeutics, a biopharmaceutical company, engages in the development of novel drugs based on proprietary integration of structural and electrical properties of biological membranes. It develops molecular nano-motors that are small-chemical entities capable of energy mining from the intra-membrane electric field. Its Apo-Si is a platform technology for the delivery of genetic drugs, such as siRNA into cells. It is involved in the development of ATT-11T, which is a conjugate of proprietary molecular nano-motor with SN-38, the active moiety of irinotecan for the treatment of solid tumors. Interna Therapeutics has a research collaboration with Bioasis Technologies Inc. to focus on the delivery of siRNA into the brain. Interna Therapeutics was formerly known as Aposense Ltd. and changed its name to Interna Therapeutics in November 2024. Interna Therapeutics was founded in 1996 and is based in Petah Tikva, Israel.